Lucid Diagnostics Announces $18 Million Underwritten Offering of Common Stock [TheStreet.com]
Lucid Diagnostics Inc. (LUCD)
Company Research
Source: TheStreet.com
NEW YORK, April 23, 2026 NEW YORK April 23, 2026 /PRNewswire/ -- Lucid Diagnostics Inc. (Nasdaq: LUCD) ("Lucid" or the "Company"), a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM), today announced the pricing of an underwritten registered direct offering of 18,000,000 common shares at a purchase price of $1.00 per share, anchored by a $15M investment from a fundamental institutional investor with support from a large existing shareholder. The gross proceeds from the offering, before deducting underwriting discounts and commissions and other estimated offering expenses, are expected to be approximately $18 million. The Company intends to use the net proceeds from this offering for working capital and general corporate purposes. The offering is expected to close on or about April 24, 2026, subject to customary closing conditions. Canaccord Genuity LLC and BTIG, LLC are acting as joint bookrunners for the offering.
Show less
Read more
Impact Snapshot
Event Time:
LUCD
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
LUCD alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
LUCD alerts
High impacting Lucid Diagnostics Inc. news events
Weekly update
A roundup of the hottest topics
LUCD
News
- Lucid Diagnostics Announces $18 Million Underwritten Offering of Common StockPR Newswire
- Lucid Diagnostics (LUCD) had its price target raised by Ascendiant Capital Markets from $8.25 to $9.00. They now have a "buy" rating on the stock.MarketBeat
- Lucid Diagnostics to Participate in Fireside Chat at the 25th Annual Needham Virtual Healthcare ConferencePR Newswire
- PAVmed Provides Business Update and Reports Fourth Quarter and Full Year 2025 Financial Results [Yahoo! Finance]Yahoo! Finance
- Lucid Diagnostics (LUCD) had its "buy" rating reaffirmed by BTIG Research. They now have a $2.50 price target on the stock.MarketBeat
LUCD
Earnings
- 3/25/26 - Miss
LUCD
Sec Filings
- 4/20/26 - Form PRE
- 4/13/26 - Form 3
- 4/3/26 - Form S-8
- LUCD's page on the SEC website